All Posts By

Todd Levine MD

Researchers Detect Alpha-Synuclein in Nerve Biopsy 6 Years Before Clinical Diagnosis of Dementia With Lewy Bodies

By Insights

Dr. Todd Levine, CND Life Sciences’ Co-Founder and CMO, will speak at the product presentation theater at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting this month. His talk, “In-Office Cutaneous Testing for Pure Autonomic Failure and Other Synucleinopathies: Introducing the Syn-One Test™,” will be held Friday, October 15 at 3:40 pm MST.

Read More

We Can Perform Early Screening for Neurodegenerative Disorders. Does That Mean We Should?

By Insights

In the November 2020 issue of Movement Disorders, Dommershuijsen and his fellow researchers in the Netherlands wrote an excellent editorial on the ethical considerations of screening for rapid eye movement sleep behavior disorder (RBD) in the healthy general population. I wanted to use this blog to discuss why this question is such an important one to consider as discoveries in the alpha-synucleinopathies continue to advance.

Read More